Autoimmune hemolytic anemia (AIHA) may be frequently challenged by infectious compli-cations, mainly as a result of immunosuppressive treatments administered. Furthermore, infectious agents are known triggers of AIHA onset and relapse. Although being risk factors for mortality, infections are an underestimated issue in AIHA. This review will collect the available evidence on the frequency and type of infectious complications in AIHA, detailing the risk related to each treatment (i.e., steroids, rituximab, splenectomy, classic immunosuppressive agents, and new target drugs). Moreover, we will briefly discuss the infectious complications in AIHA secondary to other diseases that harbor an intrinsic infectious risk (e.g., primary immunodeficiencies, systemic autoimmune diseases, lymphoproliferative disorders, solid organ and hematopoietic stem cell transplants). Finally, viral and bacterial reactivations during immune suppressive therapies will be discussed, along with suggested screening and prophylactic strategies.

Infectious complications in autoimmune hemolytic anemia / J.A. Giannotta, B. Fattizzo, F. Cavallaro, W. Barcellini. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:1(2021), pp. 164.1-164.19. [10.3390/jcm10010164]

Infectious complications in autoimmune hemolytic anemia

J.A. Giannotta
Primo
;
B. Fattizzo
Secondo
;
F. Cavallaro;
2021

Abstract

Autoimmune hemolytic anemia (AIHA) may be frequently challenged by infectious compli-cations, mainly as a result of immunosuppressive treatments administered. Furthermore, infectious agents are known triggers of AIHA onset and relapse. Although being risk factors for mortality, infections are an underestimated issue in AIHA. This review will collect the available evidence on the frequency and type of infectious complications in AIHA, detailing the risk related to each treatment (i.e., steroids, rituximab, splenectomy, classic immunosuppressive agents, and new target drugs). Moreover, we will briefly discuss the infectious complications in AIHA secondary to other diseases that harbor an intrinsic infectious risk (e.g., primary immunodeficiencies, systemic autoimmune diseases, lymphoproliferative disorders, solid organ and hematopoietic stem cell transplants). Finally, viral and bacterial reactivations during immune suppressive therapies will be discussed, along with suggested screening and prophylactic strategies.
autoimmune hemolytic anemia; steroids; rituximab; immunosuppressants; prophylaxis; viral reactivation
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
jcm-10-00164-v2-1.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 347.98 kB
Formato Adobe PDF
347.98 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/904871
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 7
social impact